Barbara Pender

Statistics

Publications

Citations

3.3K

H-Index

Active since

2015

Affiliations

Fred Hutch Cancer Center(Current)

University of Washington

University of Washington Medical Center

Seattle Children's Hospital

Barbara Pender is an author at Fred Hutch Cancer Center specializing in cancer immunotherapy, chimeric antigen receptor t-cell therapy, and immunotherapy.

Publications per year

2015–2016

Publications

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Journal of Clinical Investigation · 2016 · 2.1K citations · Full text

Medicine, Immunology, Oncology +17

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 <sup>+</sup> and CD4 <sup>+</sup> CD19-specific chimeric antigen receptor–modified T cells

Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Science Translational Medicine · 2016 · 1K citations

Medicine, Immunology, Oncology +17

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Cameron J. Turtle, Carolina Berger, Daniel Sommermeyer et al. · Blood · 2015 · 70 citations

Life Sciences, Hematology, Oncology +17

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Cameron J. Turtle, Laïla‐Aïcha Hanafi, Carolina Berger et al. · Blood · 2015 · 56 citations

Medicine, Hematology, Immunology +17

Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

Gregory A. Rufener, Oliver W. Press, Philip Olsen et al. · Cancer Immunology Research · 2016 · 32 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 7